Antipsychotics Flashcards
typical antipsychotics moa
dopamine D2 blockers; decrease positive symptoms (hallucinations, disorganization of thought and behavior)
atypical antipsychotics moa
D2 and 5-HT2A antagonism
haloperidol moa/potency
D2 block; high potency
butyrophenones
haloperidol
only approved agent for children and teens
risperidone
aripiprazole moa
D2 partial agonist, 5-HT2a antagonist; 5-HT1a partial agonist (lower incidence of side effects)
asenapine moa
D1, D2, 5-HT2, alpha adrenergic and histamine receptor antagonist (low muscarinic affinity)
anti-psychotic extrapyramidal side effects
acute dystonia, akathesia, parkinsonian syndrome, neuroleptic malignant syndrome, perioral tremor, tardive dyskinesia
acute dystonia symptoms and treatment
symptoms: muscle spasms, facial grimacind, stiff neck, oculogyric crisis
Tx: anticholinergic antiparkinsonian agents
akathesia symptoms and treatment
symptoms: strong subjective feelings of distress or discomfort often referred to the legs
Tx: decrease dose, add antiparkinsonian agent, anti anxiety agent or propranolol
neuroleptic malignant syndrome symptoms and treatment
Symptoms: fever, severe parkinsonism with catatonia, fluctuations in coarse tremor intensity, autonomic instability, elevated creatinine kinase, myoglobinemia, high mortality
Tx: cessation of antipsychotic, supportive care, dantrolene or bromocriptine
antipsychotic effects on the brainstem
decreased vasomotor reflexes at low doses
antipsychotic effects on the CTZ
protect against N./V at low doses
drugs that cause increased PRL
all typical and risperidone
little increase: clozapine, olanzapine, and ziprasidone
likely to increase risk of type 2 DM
clozapine and olanzapine
may cause jaundice
chlorpromazine
agranulocytosis
clozapine (weekly blood counts necessary)
cause skin reactions - urticaria, photosensitivity or dermatitis
phenothiazines - chlorpromazine, fluphenazine, perphenazine
most likely to cause weight gain
clozapine and olanzapine
main route of metabolism
hepatic microsomal oxidases and conjugation; most metabolites are inactive
typical: cyp 2D6 and 3A4 (inhibit)
paliperidone
active metabolite of risperidone available for therapeutic use
treatment of catatonia
benzos seem to help, if not ECT
do not give antipsychotics
if a patient is on haliperidol for 1 week and comes back complaining of agitation and trouble sitting still (akisthesia) what should you do?
decrease the dose
why do low potency typical antipsychotics have fewer EPSs?
they have greater antimuscarinic effects
-e.g. chlorpromazine and thiothixine